How to start and convert your adult patients to once-daily, long-acting Tresiba®

Step 1: Initiate1


Type 1 diabetes

Insulin naïve

1/3 to 1/2

of total daily insulin dosea

Type 2 diabetes

Insulin naïve

10 units

once daily

1:1 CONVERSION

same unit dose as total daily long- or intermediate-acting insulin dose

aThe remainder of the total daily insulin dose should be administered as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naïve patients with type 1 diabetes.

Step 2: Titrate2-4

Based on ADA and AACE Guidelines2,3

FPG Bar


The recommended time between dose increases is 3 to 4 days1

  • Tresiba® was not studied in clinical trials using this algorithm
  • Individualize and titrate the dose of Tresiba® based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal. Dose adjustments may be needed with changes in physical activity, changes in meal patterns, changes in renal or hepatic function, or during acute illness to minimize the risk of hypoglycemia or hyperglycemia1
primary_msg

Find out how to prescribe Tresiba® for your pediatric patients

See dosing

Add Tresiba® to your ePrescribing system



Tresiba® FlexTouch® U-100

Light Green FlexTouch® pen


Form/Strength:

100 units/mL

Quantity per box:

15 mL (5 x 3 mL)
1500 units total

NDC:

0169-2660-15



Tresiba® FlexTouch® U-200

Dark Green FlexTouch® pen


Form/Strength:

200 units/mL

Quantity per box:

9 mL (3 x 3 mL)
1800 units total

NDC:

0169-2550-13



Tresiba® U-100,
10-mL vial

Dark Green FlexTouch® pen


Form/Strength:

100 units/mL

Quantity per box:

1 vial (10 mL)
1000 units total

NDC:

0169-2662-11


Prescribing Tresiba®

When sending prescribing information, be sure to specify the right formulation of Tresiba® for your patients:

  • The U-100 pen has a maximum dose of 80 units per injection and is dosed in 1-unit increments
  • The U-200 pen has a maximum dose of 160 units per injection and is dosed in 2-unit increments
  • The U-100 vial holds a volume of 10 mL

 

Also be sure to include:

Starting dose (units per day)

Titration information

Separate prescription for pen needles (if necessary)

secondary_msg

See what to do when patients miss their scheduled dose of Tresiba®

Get guidance

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Please click here for Prescribing Information

 

 

References:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2018.
  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care. 2015;38(1):140-149.
  3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2017;23(2):207-238.
  4. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Adv Ther. 2013;30(6):607-622.